Preclinical and early clinical studies of 5-HT4R agonism and 5-HT6R antagonism are being conducted to investigate the ability of these approaches to alleviate cognitive deficits associated with AD (Ivachtchenko et al., 2016; Nirogi et al., 2021). This evidence concerns the gene HTR4 and Alzheimer disease.